Clinical Trials: Bone, Effects of Therapy
Therapeutic Area: Bone Turnover
Principal Investigator: Dr. Pamela Taxel
Title: The Effect of Alendronate vs. Oral Estrogen Therapy on Bone Turnover and Bone Mass in Older Men Receiving Hormonal Suppression for Prostate Cancer
Description: This study will evaluate the effect on bone health of androgen deprivation therapy (injections of medications such as luprolike or goserelin) used in the
treatment of locally advanced prostate cancer. Long-term therapy with these injections may lead to bone loss and increased risk of osteoporotic fracture. The increased incedence of
fractures, particularly of the hip, associated with aging in normal men is now considered a major public health issue. The potential for compounding this problem as a result of the
growing population of men treated with androgen deprivation therapy for locally advanced prostate carcinoma is the rationale for this study. This study will evaluate a preventive
approach using low dose estrogen or a bisphosphonate, medications that block bone breakdown.
Length/Duration: 13 months
Compensation: None
Location: UConn Health Center
For more information, patient benefits, and to learn if you qualify, contact: Dr. Pamela Taxel at 860-679-4743.
IRB #: 01-227
Therapeutic Area: Prostate Cancer
Principal Investigator: Dr. Pamela Taxel
Title: The Effect of Risedronate on Bone Turnover and Bone Mass in Older Men Receiving Neoadjuvant Therapy for Prostate Cancer
Description: This study will evaluate the effect on bone health of androgen deprivation therapy (injections of medications such as luprolide or goserelin) used in the treatment
of locally advanced prostate cancer. Long-term therapy with these injections may lead to bone loss and increased risk of osteoporotic fracture. The increased incidence of
fractures, particularly of the hip, associated with aging in normal men is now considered a major public health issue. The potential for compounding this problem as a result of the
growing population of men treated with androgen deprivation therapy for locally advanced prostate carcinoma is the rationale for this study. This study will test the effects of
androgen deprivation therapy on the skeleton, as well as evaluate a preventive approach using a bisphosphonate, a medication that blocks bone breakdown.
Length/Duration: Approximately seven months
Compensation: None
Location: UConn Health Center
For more information, patient benefits, and to learn if you qualify, contact: Dr. Pamela Taxel at 860-679-4743.
IRB #: 02-062
Therapeutic Area: Breast Cancer
Principal Investigator: Dr. Scott Kurtzman
Title: NSABP Protocol B-38: A Phase III, Adjuvant Trial Comparing Three Chemotherpy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/
Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC/P); DD ACFollowed by DD Paclitaxel Plus Gemcitabine (DD AC/PG)
Description: The study is being conducted to see if the addition of a new drug, gemcitabine to a dose-dense regimen of doxorubicin/cyclophosphamide followed by paclitaxel
is better at treating node positive breast cancer than standard docetaxel/doxorubicin/cyclophosphamide and double-dense doxorubin/cyclophosphamide followed by paclitaxel. The study
will also look at the toxicities associated with these regimens.
Length/Duration:
Compensation:
Location: UConn Health Center
For more information, patient benefits, and to learn if you qualify, contact: Kim D. Jennings at 860-679-3432.
IRB #: 05-118 |
Research
done today will be the standard treatments of tomorrow.